BENEDICT: Primary prevention of microalbuminuria in hypertensive type 2 dibetes

British Journal of Diabetes and Vascular Disease

Volumn 6, Issue 2, 2006, Pages 84-88

  Vora, Jiten ^a   Weston, Clive ^b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b SINGLETON HOSPITAL   (United Kingdom)

Author keywords

Hypertension; Microalbuminuria; Nephropathy; Trandolapril; Type 2 diabetes

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ENALAPRIL; HEMOGLOBIN A1C; LISINOPRIL; MINOXIDIL; PLACEBO; TRANDOLAPRIL; VERAPAMIL;

ADULT; ALBUMINURIA; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG CHOICE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; KIDNEY FUNCTION; MICROALBUMINURIA; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PRIMARY PREVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; SUSTAINED RELEASE PREPARATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINALYSIS;

EID: 33646580088     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514060060020601     Document Type: Article

References (18)

1. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.
2. Wild S, Roglic G, Green A et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27: 1047-53.
3. Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney International 2003;63:225-32.
4. The Royal College of General Practitioners Effective Clinical Practice Unit. Guideline entitled 'Diabetic renal disease: prevention and early management.' 2002 Accessed at: http://www.nice.org.uk/page.aspx?o=39385
5. Marshall SM. Review. Recent advances in diabetic nephropathy. Postgrad Med J 2004;80:624-33.
6. de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 2004;92:S2-S6.
7. Parving H-H, Lehnert H, Brochner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
8. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:53-9.
9. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
10. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
11. Bakris GL, Weir MR, De Quattro V et al. Effects of ACE inhibitor/calcium channel antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1996;50:1641-50.
12. de Zeeuw D, Remuzzi G, Parving H-H et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921-7.
13. Furtner M, Kiechl S, Mair A et al. Urinary albumin excretion is independently associated with carotid and femoral atherosclerosis in the general population. Euro Heart J 2005;26:279-87.
14. Ravid M, Brosh D, Levi Z et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Annals Int Med 1998;128:982-8.
15. The EUCLID study group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92.
16. Strippoli GFM, Craig M, Deeks JJ et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828-31.
17. So WY, Ozaki R, Chan NN et al. Effect of angiotensin-converting enzyme inhibition on survival in 3,773 Chinese type 2 diabetic patients. Hypertension 2004;44:294-9.
18. NICE. Inherited guideline H, 2002. Management of type 2 diabetes - management of blood pressure and blood lipids. Accessed at: http://www.nice.org.uk/page.aspx?o=38551